Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer.

Koji TakadaShinichiro KashiwagiWataru GotoYuka AsanoKatsuyuki TakahashiTsutomu TakashimaShuhei TomitaMasahiko OhsawaKosei HirakawaMasaichi Ohira

Published in: Journal of translational medicine (2018)

This study shows with the TPD regimen, a high CFR leads to a high ORR and long PFS in HER2-positive breast cancer. CFR, therefore, may be one of the important prognostic factors for this disease.

Keyphrases

positive breast cancer
combination therapy
prognostic factors
epidermal growth factor receptor
regulatory t cells
metastatic breast cancer
peripheral blood
radiation therapy
squamous cell carcinoma
tyrosine kinase
nk cells
rectal cancer